Market Chatter: Goldman Sachs Hired by Cinven to Revive $2 Billion JLA Sale

MT newswire2026/10/09 09:45

05:45 AM EDT, 10/09/2026 (MT Newswires) -- Goldman Sachs (GS) is reportedly working with buyout firm Cinven to reactivate the sale of UK commercial equipment provider JLA Group, Bloomberg News reported Friday, citing people familiar with the matter. Cinven engaged Goldman Sachs to assist with the planned sale, and a deal could value JLA between 1.5 billion pounds ($1.99 billion) and 2 billion pounds, the news outlet quoted the people as saying. Cinven previously explored a sale in 2024 but held onto the business after deciding that offers did not adequately reflect its growth prospects, the report said. JLA has about (L)650 million ($863 million) in debt maturing in 2031, including a senior secured loan and a delayed-draw credit facility, according to Bloomberg. Goldman Sachs, Cinven, and JLA Group did not immediately respond to MT Newswires' request for comment. (Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

You may also like

Starbucks (SBUX.US) officially refutes rumors: clearly denies acquiring Chipotle (CMG.US), focuses on "Back to Starbucks" transformation strategy

Starbucks publicly clarified on Monday that the company has not acquired Chipotle Mexican Grill, putting an end to the previous acquisition rumors.

智通财经•2026/10/12 23:31

BlackRock increases allocation to short-term US Treasuries and lowers US stocks: "Rate hike bets have gone too far," high yields should be prioritized

BlackRock has turned bullish on U.S. Treasury bonds for the first time in six years, upgrading short-term bonds to overweight and downgrading U.S. equities to neutral, stating that rate hike expectations are excessive and it is time to lock in yields.

智通财经•2026/10/12 23:27

AstraZeneca (AZN.US) Relizumab's new indication is expected to be included in priority review

Relizumab is a blockbuster product under AstraZeneca, with global sales projected to reach 4.718 billions USD in 2025 (YOY +20.23%).

智通财经•2026/10/12 23:11

4 Big Bank Earnings to Watch This Week as Wall Street Turns Bullish

BeInCrypto•2026/10/12 22:42